Cutaneous castleman's disease responds to anti interleukin-6 treatment. Mol Cancer Ther 2007 Sep;6(9):2386-90
Date
09/04/2007Pubmed ID
17766835DOI
10.1158/1535-7163.MCT-07-0256Scopus ID
2-s2.0-34748822990 (requires institutional sign-in at Scopus site) 46 CitationsAbstract
Castleman's disease is uncommon, and cutaneous involvement is even rarer. We report a 42-year-old Asian woman with the multicentric plasma cell variant of Castleman's disease limited to her skin. The literature suggests that Castleman's disease is driven by interleukin-6 (IL-6). Based on these data, we hypothesized that suppression of IL-6 would have a salutary effect. Therefore, our patient was treated with CNTO328, a chimeric murine anti-human IL-6 antibody. She has shown a remarkable, ongoing response to this treatment, with almost complete clearing of her skin lesions after six doses.
Author List
Ahmed B, Tschen JA, Cohen PR, Zaki MH, Rady PL, Tyring SK, Corringham RE, Kurzrock RAuthor
Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAntibodies, Monoclonal
Castleman Disease
Female
Humans
Interleukin-6
Plasma Cells
Prognosis
Skin Neoplasms